» Articles » PMID: 18083610

Hepatocellular Adenoma and Metabolic Balance in Patients with Type Ia Glycogen Storage Disease

Overview
Journal Mol Genet Metab
Specialty Endocrinology
Date 2007 Dec 18
PMID 18083610
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Glycogen storage disease type I (GSD I) is a metabolic disorder resulting from defects in the glucose-6-phosphatase system. Approximately 75% of adolescent and adult patients develop hepatocellular adenomas, which can lead to considerable morbidity and mortality. The pathogenesis of adenomas is unclear and the risk of developing adenomas in treated patients is uncertain. The objective of this study was to determine whether metabolic imbalance was related to the occurrence of adenomas in patients with GSD I, and to determine what specific biochemical pathways were involved. We performed a 1:1 case-control retrospective study; cases were GSD I patients with adenomas and controls were GSD I patients without adenomas. Controls and cases were matched according to age at diagnosis, age at adenoma detection, and gender. We investigated biochemical abnormalities indicative of metabolic balance and exogenous factors potentially related to the onset of adenomas in the two groups. We detected no significant differences in dietetic treatment, compliance to treatment, or biochemical parameters related to metabolic balance between the two groups. In conclusion, we were unable to identify any significant differences in metabolic balance between GSD I patients who developed adenomas and those who did not.

Citing Articles

Liver Transplantation for Hepatic Adenoma: A UNOS Database Analysis and Systematic Review of the Literature.

Ziogas I, Tasoudis P, Serifis N, Alexopoulos S, Montenovo M, Shingina A Transplant Direct. 2022; 8(2):e1264.

PMID: 35018302 PMC: 8735769. DOI: 10.1097/TXD.0000000000001264.


A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection.

Klompenhouwer A, van Rosmalen B, Haring M, Thomeer M, Doukas M, Verheij J Liver Int. 2020; 40(9):2272-2278.

PMID: 32279413 PMC: 7497037. DOI: 10.1111/liv.14467.


Development of Hepatocellular Carcinoma in Patients with Glycogen Storage Disease: a Single Center Retrospective Study.

Jang H, Yang H, Ko J, Moon J, Chang J, Seo J J Korean Med Sci. 2020; 35(1):e5.

PMID: 31898434 PMC: 6942134. DOI: 10.3346/jkms.2020.35.e5.


Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.

Waskowicz L, Zhou J, Landau D, Brooks E, Lim A, Yavarow Z Hum Mol Genet. 2018; 28(1):143-154.

PMID: 30256948 PMC: 6298237. DOI: 10.1093/hmg/ddy343.


Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.

Brooks E, Landau D, Everitt J, Brown T, Grady K, Waskowicz L J Inherit Metab Dis. 2018; 41(6):965-976.

PMID: 30043186 PMC: 6328337. DOI: 10.1007/s10545-018-0223-y.